Akari Therapeutics plc ADR (0.01 USD) (AKTX) is a publicly traded Healthcare sector company. As of May 21, 2026, AKTX trades at $3.51 with a market cap of $4.01M and a P/E ratio of 0.00. AKTX moved +0.53% today. Year to date, AKTX is -70.85%; over the trailing twelve months it is -93.40%. Its 52-week range spans $3.02 to $148.00. Analyst consensus is buy with an average price target of $27.00. Rallies surfaces AKTX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Who owns AKTX stock?
Hedge funds tracked by Rallies that own AKTX include Renaissance Technologies. The latest tracked quarter is Dec 31, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Akari Therapeutics plc ADR (0.01 USD).
AKTX Key Metrics
Key financial metrics for AKTX
Metric
Value
Price
$3.51
Market Cap
$4.01M
P/E Ratio
0.00
EPS
$0.00
Dividend Yield
0.00%
52-Week High
$148.00
52-Week Low
$3.02
Volume
3.10K
Avg Volume
0
Revenue (TTM)
$0
Net Income
$-17.30M
Gross Margin
0.00%
Top Hedge Funds Holding AKTX
Renaissance Technologies holds 23.46K shares of AKTX, changed +29.86% as of Dec 31, 2024.
Hedge funds tracked by Rallies that own AKTX include Renaissance Technologies. The latest tracked quarter is Dec 31, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Akari Therapeutics plc ADR (0.01 USD).
Does Rallies show 13F holders for AKTX?
Yes. Rallies tracks hedge fund and 13F ownership data for AKTX, including fund names, share counts, latest tracked quarter, and position changes when available.
Is AKTX research on Rallies investment advice?
No. Rallies provides research, data, and educational context for AKTX. It does not provide personalized investment advice.
